Savvy Updates 7/29/24: Abbott FS Libre 3 Sensors Warning, Dexcom Stock Plummets, T1Ds Fear GLP-1s Will Edge Out Insulin, Sleep Apnea & Retinopathy, Diamyd Fast-Tracked, Shuren Leaves FDA CDRH, T1D Moonshot Robert Oringer, Embecta Considers Sale, SmartStart’s Interactive Educational Platform
Abbott Issues Warning for Certain FreeStyle Libre 3 Sensors by Paul Heltzel for diaTribe.org, 25 July 2024. Some FreeStyle Libre 3 continuous glucose monitoring sensors could display false high readings and should be immediately discontinued, urged the manufacturer....
Savvy Updates 7/22/24: ALERT: Dexcom G7 & Geofencing, Sensulin Glucose-Responsive Insulin, Bulsai Infrared Sensor for Placing for Insulin Injections, iAPS/Trio DIY Insulin Algorithm, Replica Health Personalized Metabolic Healthcare, Free Lifetime US National Parks Pass
Dexcom G7 & Geofencing: Travel Alert If you are a Dexcom G7 user or using MDI with connection to phone app, PLEASE READ: you are planning travel shortly away from your home country, and you use open-source DIY app or MDI or Mobi or will use O5 with G7 Dexcom G7 is...
Savvy Updates 7/15/24: Novo Icodec Rejected by FDA, Is Stevia Safe?, Sucrolose & Environment, BG Changes Impact Cognitive Function, Ypsomed Pump, Islet Cell Replacement Therapy, FTC to Sue 3 Largest PBMs, GO-Pen Creates Equal Access, Medicare Cuts Physician Pay
Novo’s once-weekly insulin rejected by FDA by Kristin Jensen for BioPharmaDive.com, 11 July 2024. Novo is one of the world’s premier manufacturers, along with Indianapolis-based Eli Lilly. Both have been working for years to offer patients a more convenient option...
Savvy Updates 7/8/24: Warning about Fake GLP-1, PBMs & The Business of Diabetes with Scott Strumello, Insulin-Triggering Nutrients, Diabetes Burnout, Wholeness Mantra
A Warning about Counterfeit Mounjaro, Ozempic, and Other Diabetes Medications by Dr. Steven Edelman for TCOYD, 1 July, 2024. Counterfeit Medications Are a Global Problem: Since the beginning of time, disreputable individuals have tried to make a profit off of...
Savvy Updates 7/1/24: Senseonics 365-day CGM, Dana Lewis on Exocrine Pancreatic Insufficiency, Apple/Fitbit/Garmin & Bacteria, Low-Dose SGLT2 Inhibitor May Protect Kidneys, Dual GLP-1 & Glucagon Agonist Pemvidutide, How GLP-1 Receptor Agonists Work
Senseonics tips 365-day CGM to double 2025 sales by Nick Paul Taylor for MedTechDive.com, 25 June 2024. In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current...
More Diabetes Blogs